In this issue of Cancer Cell, Yang et al. report the third in a series of phase III trials that demonstrates the survival benefit of combining a PD-1 inhibitor with chemotherapy in nasopharyngeal cancer. A gene expression analysis identifies "hot" and "cold" tumor signatures with prognostic and predictive significance.
View details for DOI 10.1016/j.ccell.2023.04.013
View details for Web of Science ID 001024475200001
View details for PubMedID 37207653